Literature DB >> 10803463

Nonrandom 4p13 rearrangements of the RhoH/TTF gene, encoding a GTP-binding protein, in non-Hodgkin's lymphoma and multiple myeloma.

C Preudhomme1, C Roumier, M P Hildebrand, E Dallery-Prudhomme, D Lantoine, J L Laï, A Daudignon, C Adenis, F Bauters, P Fenaux, J P Kerckaert, S Galiègue-Zouitina.   

Abstract

We recently isolated the RhoH/TTF gene by its fusion to the LAZ3/BCL6 gene, in a non-Hodgkin's lymphoma (NHL) cell line, which bore a t(3;4)(q27;p11-13) translocation. This gene encodes a novel Rho GTP-binding protein and is specifically expressed in hematopoietic tissues. We made its precise mapping at band 4p13, and described its partial genomic structure. Using fluorescence in situ hybridization and molecular analyses, we report here on the rearrangement of the RhoH/TTF gene, at band 4p13, in four cases of NHL with t(3;4)(q27;p13) translocation and its fusion to the LAZ3/BCL6 gene at band 3q27, in three of these cases. RT-PCR analysis of two cases allowed the detection of variable fusion transcripts emerging from the rearranged alleles, and in one case, a deregulated expression of both RhoH/TTF and LAZ3/BCL6 genes, by promoter substitution, was observed. We also show here another rearrangement of the RhoH/TTF gene in a patient with multiple myeloma and t(4;14)(p13;q32) translocation, with breakage within the IGH gene. It is the first report which describes the recurrent chromosomal alteration of a GTP-binding protein encoding gene, in patients with hematopoietic malignancies.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10803463     DOI: 10.1038/sj.onc.1203521

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  34 in total

1.  The hematopoiesis-specific GTP-binding protein RhoH is GTPase deficient and modulates activities of other Rho GTPases by an inhibitory function.

Authors:  Xiaoyu Li; Xia Bu; Binfeng Lu; Hava Avraham; Richard A Flavell; Bing Lim
Journal:  Mol Cell Biol       Date:  2002-02       Impact factor: 4.272

2.  Involvement of Rho family GTPases in p19Arf- and p53-mediated proliferation of primary mouse embryonic fibroblasts.

Authors:  Fukun Guo; Yi Zheng
Journal:  Mol Cell Biol       Date:  2004-02       Impact factor: 4.272

Review 3.  Rho GTPases: functions and association with cancer.

Authors:  Saskia I J Ellenbroek; John G Collard
Journal:  Clin Exp Metastasis       Date:  2007-11-14       Impact factor: 5.150

4.  CAAX-box protein, prenylation process and carcinogenesis.

Authors:  Juehua Gao; Jie Liao; Guang-Yu Yang
Journal:  Am J Transl Res       Date:  2009-05-25       Impact factor: 4.060

5.  RhoH is critical for cell-microenvironment interactions in chronic lymphocytic leukemia in mice and humans.

Authors:  Anja Troeger; Amy J Johnson; Jenna Wood; William G Blum; Leslie A Andritsos; John C Byrd; David A Williams
Journal:  Blood       Date:  2012-04-03       Impact factor: 22.113

6.  RhoH participates in a multi-protein complex with the zinc finger protein kaiso that regulates both cytoskeletal structures and chemokine-induced T cells.

Authors:  Akihisa Mino; Anja Troeger; Christian Brendel; Alan Cantor; Chad Harris; Marioara F Ciuculescu; David A Williams
Journal:  Small GTPases       Date:  2016-08-31

Review 7.  Cell growth and metastasis in pancreatic cancer: is Vav the Rho'd to activation?

Authors:  Daniel D Billadeau
Journal:  Int J Gastrointest Cancer       Date:  2002

Review 8.  Rho GTPases in hematopoiesis and hemopathies.

Authors:  James C Mulloy; Jose A Cancelas; Marie-Dominique Filippi; Theodosia A Kalfa; Fukun Guo; Yi Zheng
Journal:  Blood       Date:  2009-11-24       Impact factor: 22.113

9.  Rac and Rho GTPases in cancer cell motility control.

Authors:  Matteo Parri; Paola Chiarugi
Journal:  Cell Commun Signal       Date:  2010-09-07       Impact factor: 5.712

10.  RhoH regulates subcellular localization of ZAP-70 and Lck in T cell receptor signaling.

Authors:  Hee-Don Chae; Jamie E Siefring; David A Hildeman; Yi Gu; David A Williams
Journal:  PLoS One       Date:  2010-11-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.